About
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Current Value
$6.551 Year Return
Current Value
$6.551 Year Return
Key Details
Market Cap
$353.11M
P/E Ratio
-1.52
1Y Stock Return
-65.19%
1Y Revenue Growth
-7.66%
Dividend Yield
0.00%
Price to Book
1.3
Strategies that include RGNX
Double maintains 1 strategies that include RGNX - REGENXBIO, Inc.
Medium risk
$13,000
0.00%
Health Care Sector
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
348
Stock's related to RGNX
The stocks that are correlated to RGNX - REGENXBIO, Inc. are RCKT, DNLI, NTLA, ARWR, FATE
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| 53.20% | $671.77M | -75.23% | 0.00% | |
| 51.78% | $2.00B | -29.07% | 0.00% | |
| 49.46% | $755.67M | -70.78% | 0.00% | |
| 47.29% | $1.74B | -52.08% | 0.00% | |
| 47.09% | $88.24M | -89.02% | 0.00% | |
| 46.85% | $188.26M | -63.53% | 0.00% | |
| 46.50% | $2.77B | -9.77% | 0.00% | |
A ALNTAllient, Inc. | 46.01% | $374.22M | -33.95% | 0.59% |
| 45.32% | $1.85B | -37.74% | 0.00% | |
| 44.71% | $12.59B | -13.92% | 1.91% | |
| 44.67% | $5.13B | -13.10% | 4.04% | |
| 44.65% | $2.93B | -47.07% | 0.00% | |
| 44.65% | $2.13B | -40.76% | 0.00% | |
A ALECAlector, Inc. | 43.65% | $116.92M | -79.97% | 0.00% |
N NNOXNano-X Imaging Ltd. | 43.17% | $287.24M | -54.79% | 0.00% |
B BLDTopBuild Corp. | 43.17% | $9.15B | -29.15% | 0.00% |
A ACLXArcellx, Inc. | 43.08% | $3.69B | +6.38% | 0.00% |
| 42.94% | $3.29B | +27.07% | 0.00% | |
L LYFTLyft, Inc. | 42.71% | $5.41B | -29.16% | 0.00% |
K KBHKB Home | 42.51% | $4.21B | -13.57% | 1.81% |
ETF's related to RGNX
The ETFs that are correlated to RGNX - REGENXBIO, Inc. are CPRJ, GNOM, XBI, IWC, IBB
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 58.49% | $48.38M | 0.69% | |
| 57.90% | $47.13M | 0.5% | |
X XBISPDR Biotech ETF | 56.92% | $4.76B | 0.35% |
| 54.87% | $797.08M | 0.6% | |
| 54.09% | $5.61B | 0.45% | |
| 53.32% | $936.86M | 0.75% | |
| 50.67% | $10.92B | 0.07% | |
| 50.57% | $62.65B | 0.19% | |
| 50.57% | $10.72B | 0.24% | |
| 50.20% | $144.85M | 0.79% | |
| 49.63% | $317.59M | 0.79% | |
| 49.29% | $15.94B | 0.04% | |
| 48.91% | $514.19M | 0.2% | |
| 48.67% | $10.95B | 0.24% | |
| 48.17% | $1.29B | 0.15% | |
| 47.99% | $1.76B | 0.17% | |
| 47.98% | $1.10B | 0.31% | |
| 47.84% | $155.05M | 0.79% | |
| 47.57% | $2.34B | 0.39% | |
| 47.40% | $224.98M | 0.58% | |
News
Yahoo
Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit
SeekingAlpha
Undercovered Dozen: Delek Logistics, Perma-Fix, Consolidated Water, Rockwell Automation +
SeekingAlpha
Regenxbio Inc. is ranked a Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and major buyout potential. Click for more on RGNX stock.
SeekingAlpha
Stay updated with Wall Street's weekly highlights: key inflation data, CoreWeave IPO, and earnings reports. Insights on biotech trends & top stock picks.
Yahoo
The interim data found one child in the Duchenne trial produced more than double the amount of the protein needed to maintain muscle integrity compared with control.
Yahoo
REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202, a differentiated investigational gene therapy for Duchenne muscular dystrophy (Duchenne). Results were presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds